This article is for informational and educational purposes only and does not constitute medical advice. Vesugen is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Vesugen is a synthetic tripeptide with the sequence Lys-Glu-Asp (KED) and a molecular weight of approximately 390 Da. It belongs to the peptide bioregulator class developed by the research group of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology — the same group responsible for Epitalon (Ala-Glu-Asp-Gly), Pinealon (Glu-Asp-Arg), Cartalax (Ala-Glu-Asp), and related tissue-targeted synthetic peptides. Vesugen was developed from research involving vascular tissue-derived peptide fractions and is proposed to modulate gene expression in vascular endothelial cells, the cell type lining blood vessel walls and central to vascular homeostasis. In vitro and animal model studies, conducted predominantly by the originating research group, have examined associations between Vesugen and endothelial cell activity parameters. As with other members of the Khavinson bioregulator class, the published evidence base for Vesugen is limited primarily to studies from the originating laboratory, with most research appearing in Russian-language or limited-circulation journals. No peer-reviewed randomized controlled trial evaluating Vesugen in human subjects has been identified as of the review date.
1. Background
1.1 Peptide Bioregulators — The Khavinson Framework
The peptide bioregulator concept was developed in the Soviet Union and subsequently Russia beginning in the 1970s by Vladimir Khavinson and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg. The foundational hypothesis proposes that short peptides — typically 2–4 amino acids derived from or modeled on organ-specific tissue extracts — can regulate gene expression in a tissue-targeted manner, with proposed applications in aging biology and age-related disease. The proposed mechanism involves direct interaction of these short peptides with DNA regulatory elements such as gene promoter sequences, influencing transcription of genes relevant to the targeted tissue type [3].
The class encompasses a range of named compounds each proposed to target a specific tissue: Epitalon (Ala-Glu-Asp-Gly) for the pineal gland, Pinealon (Glu-Asp-Arg) for pineal and neuroprotective applications, Cartalax (Ala-Glu-Asp) for cartilage, and Vesugen (Lys-Glu-Asp) for vascular tissue. The biological basis for tissue-specificity — how a short circulating peptide would preferentially regulate gene expression in endothelial cells rather than other tissues encountered systemically — has not been independently established through mechanistic research [1].
1.2 Vascular Endothelium and Age-Related Changes
The vascular endothelium is a continuous monolayer of specialized cells lining the luminal surface of all blood vessels, from the aorta to the smallest capillaries. Far more than a passive barrier, the endothelium is an active signaling interface that regulates vascular tone through nitric oxide (NO) and other vasoactive mediators, controls leukocyte and platelet interactions with the vessel wall, governs vascular permeability, and modulates coagulation balance. These functions are collectively referred to as endothelial function, and their impairment — endothelial dysfunction — is considered an early and mechanistically important feature of vascular disease [4].
With aging, endothelial cells accumulate oxidative damage, reduce nitric oxide bioavailability, increase expression of adhesion molecules and inflammatory mediators, and exhibit features of cellular senescence. Structural changes in the vascular wall accompany endothelial dysfunction: elastin cross-linking increases arterial stiffness, collagen accumulates in the intima and media, and the balance between matrix synthesis and degradation shifts toward a pro-fibrotic state. These age-related vascular changes are associated with increased risk of cardiovascular disease and have motivated research into approaches that might support endothelial or vascular wall homeostasis [5].
1.3 Development of Vesugen
Vesugen was developed by the Khavinson group using the approach applied across the peptide bioregulator program: isolation and characterization of bioactive peptide fractions from vascular tissue, followed by synthesis and study of short peptide candidates identified from those fractions. The KED tripeptide sequence was selected as a proposed vascular bioregulator and subsequently examined in cell-based and animal model systems by the originating group. Published research on Vesugen specific to this compound is sparse in major English-language databases, and most available evidence appears within the broader Khavinson bioregulator literature rather than in compound-specific primary studies.
2. Molecular Structure
Vesugen is a tripeptide with the sequence Lys-Glu-Asp, abbreviated in single-letter code as KED. Its three residues carry distinct side-chain charges at physiological pH: lysine bears a positive charge, while glutamic acid and aspartic acid each carry a negative charge, giving Vesugen a net charge of approximately −1 at pH 7.4.
| Property | Detail |
|---|---|
| Sequence | Lys-Glu-Asp (KED) |
| Peptide length | 3 amino acids (tripeptide) |
| Molecular weight | ~390 Da |
| Net charge (pH 7.4) | −1 (Lys +1; Glu −1; Asp −1) |
| Related bioregulators | Vilon (Lys-Glu, KE); Cartalax (Ala-Glu-Asp, AED); Epitalon (Ala-Glu-Asp-Gly, AEDG) |
| Proposed tissue target | Vascular endothelium / vessel wall |
| Developer | Khavinson group, St. Petersburg Institute of Bioregulation and Gerontology |
3. Proposed Mechanisms
The proposed mechanisms of Vesugen follow the general bioregulator framework applied by the Khavinson group across the peptide class. Each proposed mechanism below has not been independently validated through research outside the originating group, and the label “Proposed” in each card reflects this status.
4. Key Research Findings
4.1 In Vitro Endothelial Cell Studies
Cell-based studies from the Khavinson group have examined Vesugen in endothelial cell culture models, reporting associations with parameters of cell viability, proliferation, and markers related to endothelial function under standard and stress conditions. These studies follow the methodology common to the broader bioregulator research program: exposure of cultured endothelial cells to the KED peptide, followed by assessment of target gene or protein expression using standard molecular biology assays. Reported associations are generally directionally consistent with the proposed vascular bioregulator concept, though effect magnitude, concentration dependence, and specificity relative to other short peptides have not been characterized in published independent studies.
As with other Khavinson peptide bioregulators, cell culture data cannot account for the pharmacokinetic factors that would determine whether Vesugen reaches endothelial cells at biologically relevant concentrations after systemic administration. Tripeptides are subject to rapid degradation by plasma peptidases, and the in vivo relevance of in vitro concentration ranges used in cell culture studies has not been established.
4.2 Animal Model Studies
Animal studies examining Vesugen effects on vascular tissue parameters have been conducted within the Khavinson group’s research program. These have generally employed rodent models and examined histological or biochemical markers of vascular wall structure and endothelial morphology. Published studies from the originating group report associations interpreted by the originating group as consistent with the bioregulator hypothesis in assessed vascular parameters, though the methodological details, dosing protocols, and reproducibility of these findings across independent studies or animal models remain incompletely characterized in accessible English-language literature.
4.3 Class Context and Related Bioregulators
Vesugen shares structural and conceptual features with other members of the Khavinson class. Its Glu-Asp dipeptide C-terminal sequence appears in several related bioregulators, including Cartalax (Ala-Glu-Asp) and Epitalon (Ala-Glu-Asp-Gly). Additionally, the Lys-Glu dipeptide at positions 1–2 of Vesugen is identical to Vilon (Lys-Glu), a two-residue bioregulator proposed to target immune tissue. Anisimov and Khavinson (2010) reviewed the broader class evidence base, situating Vesugen within the vascular-targeted arm of the bioregulator program and noting the general aging-biology rationale for the compound series [2]. Whether the partial sequence overlaps among class members have pharmacological implications — or whether each compound behaves as a distinct pharmacological entity — has not been investigated in published independent studies.
Qualitative representation of the relative volume and stage of available evidence for Vesugen. Bar lengths are schematic and do not represent quantitative study counts. All available research originates from the Khavinson group; independent replication has not been published as of the review date.
5. Evidence Status
| Proposed Effect / Claim | Current Status | Evidence Level |
|---|---|---|
| Gene promoter interaction (in silico) | Computational modeling from originating group; no independent experimental validation published | Limited |
| Endothelial cell activity modulation (in vitro) | Cell-based studies from originating group; not independently replicated in published literature | Limited |
| Vascular tissue parameters (animal models) | Animal studies from originating group; limited accessible detail; not independently replicated | Limited |
| Vascular matrix protein regulation | Proposed from class-level framework; Vesugen-specific independent data not published | Limited |
| Endothelial anti-inflammatory effects | Proposed from class-level framework; not independently characterized for Vesugen specifically | Limited |
| Efficacy or safety in humans (any indication) | No peer-reviewed randomized controlled trial identified as of the review date | Limited |
What We Still Don’t Know
- Human pharmacokinetics and plasma stability: Whether the KED tripeptide survives intact in human plasma long enough to reach vascular endothelial cells at biologically relevant concentrations has not been characterized in published pharmacokinetic studies. Tripeptides are subject to rapid degradation by plasma aminopeptidases and dipeptidases, and the in vivo persistence of Vesugen following any route of administration has not been published.
- Mechanism of endothelial tissue selectivity: The basis by which Vesugen would preferentially influence gene expression in endothelial cells rather than other cell types encountered after systemic administration has not been mechanistically explained or independently demonstrated. This remains an unresolved fundamental question across the Khavinson bioregulator class.
- Concentration-response relationships: The concentration of KED peptide required to produce the effects observed in cell culture models — and whether those concentrations can be achieved in the vascular wall following systemic administration — has not been established in published research.
- Long-term safety: No published preclinical toxicology data or human safety information are available for Vesugen. The effects of chronic tripeptide exposure on endothelial cell biology, systemic vascular parameters, or off-target tissues are unknown from published evidence.
- Independent replication: No study from a research group independent of the Khavinson laboratory has published findings specific to Vesugen in peer-reviewed form as of the review date. Reproducibility of any reported association therefore cannot be assessed from the available literature.
6. Limitations of Current Research
References
- Khavinson VKh, Morozov VG. “Peptides of pineal gland and thymus prolong human life.” Neuroendocrinology Letters. 2003;24(3–4):233–240.
- Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology. 2010;11(2):139–149. doi:10.1007/s10522-009-9249-8
- Tarnovskaya SI, Khavinson VKh, Linkova NS, Pronyaeva VE, Kolchina NV, Tendler SM. “Mechanism of short peptides interaction with DNA.” Advances in Gerontology. 2014;27(4):706–714.
- Brandes RP, Fleming I, Busse R. “Endothelial aging.” Cardiovascular Research. 2005;66(2):286–294. doi:10.1016/j.cardiores.2004.12.027
- Erusalimsky JD. “Vascular endothelial senescence: from mechanisms to pathophysiology.” Journal of Applied Physiology. 2009;106(1):326–332. doi:10.1152/japplphysiol.91200.2008